Iqbal, A.; May, U.; Prince, S.N.; Järvinen, T.A.H.; Heydemann, A.
Systemically Administered Homing Peptide Targets Dystrophic Lesions and Delivers Transforming Growth Factor-β (TGFβ) Inhibitor to Attenuate Murine Muscular Dystrophy Pathology. Pharmaceutics 2021, 13, 1506.
https://doi.org/10.3390/pharmaceutics13091506
AMA Style
Iqbal A, May U, Prince SN, Järvinen TAH, Heydemann A.
Systemically Administered Homing Peptide Targets Dystrophic Lesions and Delivers Transforming Growth Factor-β (TGFβ) Inhibitor to Attenuate Murine Muscular Dystrophy Pathology. Pharmaceutics. 2021; 13(9):1506.
https://doi.org/10.3390/pharmaceutics13091506
Chicago/Turabian Style
Iqbal, Aqsa, Ulrike May, Stuart N. Prince, Tero A.H. Järvinen, and Ahlke Heydemann.
2021. "Systemically Administered Homing Peptide Targets Dystrophic Lesions and Delivers Transforming Growth Factor-β (TGFβ) Inhibitor to Attenuate Murine Muscular Dystrophy Pathology" Pharmaceutics 13, no. 9: 1506.
https://doi.org/10.3390/pharmaceutics13091506
APA Style
Iqbal, A., May, U., Prince, S. N., Järvinen, T. A. H., & Heydemann, A.
(2021). Systemically Administered Homing Peptide Targets Dystrophic Lesions and Delivers Transforming Growth Factor-β (TGFβ) Inhibitor to Attenuate Murine Muscular Dystrophy Pathology. Pharmaceutics, 13(9), 1506.
https://doi.org/10.3390/pharmaceutics13091506